IMPACT OF TANEZUMAB ON HEALTH STATUS, DAILY ACTIVITY AND WORK PRODUCTIVITY IN ADULTS WITH MODERATE-TO-SEVERE OSTEOARTHRITIS

被引：0
|
作者：
Conaghan, P. G. [1 ]
Abraham, L. [2 ]
Viktrup, L. [3 ]
Cislo, P. [4 ]
机构：
[1] Univ Leeds, Leeds, W Yorkshire, England
[2] Pfizer Ltd, Tadworth, Surrey, England
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS55
引用
收藏
页码：S601 / S601
页数：1
相关论文
共 50 条
  • [31] Impact of physical activity on activity of daily living in moderate to severe dementia: a critical review
    Burge, Elisabeth
    Kuhne, Nicolas
    Berchtold, Andre
    Maupetit, Christine
    von Gunten, Armin
    [J]. EUROPEAN REVIEW OF AGING AND PHYSICAL ACTIVITY, 2012, 9 (01) : 27 - 39
  • [32] EFFECTIVENESS AND SAFETY OF ANTI-TNF AGENTS IN TREATMENT OF MODERATE TO SEVERE PSORIASIS VULGARIS: RESULTS OF WORK PRODUCTIVITY AND DAILY ACTIVITY IMPAIRMENT
    Koc, E.
    Ozarmagan, G.
    Alper, S.
    Ozgoztasi, O.
    Tekin, N. S.
    Balci, D. D.
    Onsun, N.
    Tuzun, Y.
    Atakan, N.
    Ozturkcan, S.
    Kokturk, A.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A516 - A516
  • [33] Impact of mepolizumab on work productivity and activity impairment in severe eosinophilic asthma
    Gunsoy, Necdet B.
    Cockle, Sarah M.
    Albers, Frank C.
    Doyle, Scott
    Cristancho, Rafael Alfonso
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [34] ECONOMIC IMPACT OF UPADACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE CROHN'S DISEASE AND ULCERATIVE COLITIS: INDUCTION AND MAINTENANCE PHASE 3 RESULTS ON WORK PRODUCTIVITY LOSS
    Yu, T.
    Dulai, P. S.
    Griffith, J.
    Sharma, D.
    Loftus, E., V
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S131 - S132
  • [35] Health-Related Quality of Life and Work Productivity in patients with moderate-to-severe Inflammatory Bowel Disease in Argentina: Data from the RISE AR study
    Correa, G. J.
    Yantorno, M.
    Olivera Sendra, P.
    Lasa, J. S.
    Lubrano, P.
    Balderramo, D. C.
    Zubiaurre, I.
    Ruffinengo, O.
    Brion, I.
    Leonardi, D. B.
    El-Hakeh, J.
    Guimaraens, P. N.
    Sambuelli, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S430 - S431
  • [36] Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: Results from PHOENIX 2
    Reich, Kristian
    Schenkel, Brad
    Zhao, Ning
    Szapary, Philippe
    Augustin, Matthias
    Bourcier, Marc
    Guenther, Lyn
    Langley, Richard G.
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2011, 22 (06) : 337 - 347
  • [37] THE BUDGET IMPACT OF BRODALUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS ON US COMMERCIAL HEALTH PLANS
    Feldman, S. R.
    Wu, J. J.
    Rastogi, S.
    Menges, B.
    Lingohr-Smith, M.
    Lin, J.
    [J]. VALUE IN HEALTH, 2018, 21 : S239 - S240
  • [38] Understanding the Relationship Between Pruritus Severity and Work Productivity in Patients With Moderate-to-Severe Psoriasis: Sleep Problems Are a Mediating Factor
    Kimball, A. B.
    Edson-Heredia, E.
    Zhu, B.
    Guo, J.
    Maeda-Chubachi, T.
    Shen, W.
    Bianchi, M. T.
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2016, 15 (02) : 183 - 188
  • [39] The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans
    Feldman, Steven R.
    Wu, Jashin J.
    Rastogi, Shipra
    Menges, Brandy
    Lingohr-Smith, Melissa
    Lin, Jay
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (05) : 537 - 541
  • [40] The impact of severity of atopic dermatitis on patient-reported outcomes of adults with moderate-to-severe atopic dermatitis
    Vietri, Jeffrey
    Nyberg, Fredrik
    Varol, Nebibe
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB254 - AB254
12345